Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Every word you type has to appear somewhere in the question, and the closest matches are ranked first.
75,239 questions in 5,342 reviews
current versionsNo studies 15,213 · 20.2%Ungraded 10,323 · 13.7%Very low 17,528 · 23.3%Low 17,951 · 23.9%Moderate 11,190 · 14.9%High 3,034 · 4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Intervention NR Length of stay on the intensive care unit (days) · Adult patients with SIRS or sepsis N‐acetylcysteine for sepsis and systemic inflammatory response in adults (2012) · Cochrane | no estimate extracted | 19 studies · 1309 participants | Moderate |
Intervention NR Duration of mechanical ventilation (days) · Adult patients with SIRS or sepsis N‐acetylcysteine for sepsis and systemic inflammatory response in adults (2012) · Cochrane | no estimate extracted | 9 studies · 423 participants | Moderate |
Intervention NR Incidence of new organ failure · Adult patients with SIRS or sepsis N‐acetylcysteine for sepsis and systemic inflammatory response in adults (2012) · Cochrane | RR 1.01 [0.8, 1.27] | 12 studies · 1224 participants | Moderate |
Intervention NR Mortality 4 to 5 years · Adults with mild hypertension and no cardiovascular disease Pharmacotherapy for mild hypertension (2012) · Cochrane | RR 0.85 [0.63, 1.15] | 4 studies · 8912 participants | Very low |
Intervention NR Total CV events 5 years · Adults with mild hypertension and no cardiovascular disease Pharmacotherapy for mild hypertension (2012) · Cochrane | RR 0.97 [0.72, 1.32] | 3 studies · 7080 participants | Very low |
Intervention NR Withdrawals due to adverse effects 5 years · Adults with mild hypertension and no cardiovascular disease Pharmacotherapy for mild hypertension (2012) · Cochrane | RR 4.8 [4.14, 5.57] | 1 study · 17354 participants | Moderate |
Intervention NR Length of hospital stay Days · parents of high‐risk newborn infants Telemedicine for the support of parents of high‐risk newborn infants (2012) · Cochrane | no estimate extracted | 1 study · 56 participants | Very low |
Combined inhalers vs LABAs Annual Exacerbation Rates · COPD Combined corticosteroid and long‐acting beta₂‐agonist in one inhaler versus long‐acting beta₂‐agonists for… (2012) · Cochrane | Rate ratio 0.76 [0.68, 0.84] | 9 studies · 99211 participants | Low |
Combined inhalers vs LABAs Number of people experiencing one or more exacerbations · COPD Combined corticosteroid and long‐acting beta₂‐agonist in one inhaler versus long‐acting beta₂‐agonists for… (2012) · Cochrane | OR 0.83 [0.7, 0.98] | 6 studies · 3357 participants | Moderate |
Combined inhalers vs LABAs Annual hospitalisation rates · COPD Combined corticosteroid and long‐acting beta₂‐agonist in one inhaler versus long‐acting beta₂‐agonists for… (2012) · Cochrane | Rate ratio 0.79 [0.55, 1.13] | 3 studies · 48791 participants | Very low |
Combined inhalers vs LABAs Mortality · COPD Combined corticosteroid and long‐acting beta₂‐agonist in one inhaler versus long‐acting beta₂‐agonists for… (2012) · Cochrane | OR 0.92 [0.76, 1.11] | 10 studies · 10681 participants | Moderate |
Combined inhalers vs LABAs Pneumonia · COPD Combined corticosteroid and long‐acting beta₂‐agonist in one inhaler versus long‐acting beta₂‐agonists for… (2012) · Cochrane | OR 1.55 [1.2, 2.01] | 12 studies · 11076 participants | Moderate |
Single‐dose vs short‐course (3‐7 days) antibiotics Persistent bacteriuria · children with lower urinary tract infection Antibiotics for treating lower urinary tract infection in children (2012) · Cochrane | RR 1.3 [0.65, 2.62] | 2 studies · 145 participants | Very low |
Intervention NR Re‐infection · children with lower urinary tract infection Antibiotics for treating lower urinary tract infection in children (2012) · Cochrane | RR 0.88 [0.44, 1.74] | 2 studies · 211 participants | Very low |
10‐day trimethoprim vs 10‐day trimethoprim+sulfamethoxazole Persistent bacteriuria · children with lower urinary tract infection Antibiotics for treating lower urinary tract infection in children (2012) · Cochrane | RR 1.93 [0.38, 9.76] | 1 study · 59 participants | Very low |
10‐day trimethoprim vs 10‐day trimethoprim+sulfamethoxazole Persistent symptoms · children with lower urinary tract infection Antibiotics for treating lower urinary tract infection in children (2012) · Cochrane | RR 4.84 [0.24, 96.66] | 1 study · 59 participants | Very low |
10‐day trimethoprim vs 10‐day trimethoprim+sulfamethoxazole Recurrence · children with lower urinary tract infection Antibiotics for treating lower urinary tract infection in children (2012) · Cochrane | RR 2.9 [0.12, 68.5] | 1 study · 59 participants | Very low |
10‐day cefadroxil vs 10‐day ampicillin Persistent bacteriuria · children with lower urinary tract infection Antibiotics for treating lower urinary tract infection in children (2012) · Cochrane | RR 0.33 [0.01, 7.62] | 1 study · 32 participants | Very low |
10‐day cefadroxil vs 10‐day ampicillin Persistent symptoms · children with lower urinary tract infection Antibiotics for treating lower urinary tract infection in children (2012) · Cochrane | RR 0.33 [0.01, 7.62] | 1 study · 32 participants | Very low |
Single‐dose fosfomycin vs single‐dose netilmicin Persistent bacteriuria · children with lower urinary tract infection Antibiotics for treating lower urinary tract infection in children (2012) · Cochrane | RR 3.15 [0.68, 14.64] | 1 study · 135 participants | Very low |
Single‐dose fosfomycin vs single‐dose netilmicin Recurrence · children with lower urinary tract infection Antibiotics for treating lower urinary tract infection in children (2012) · Cochrane | RR 0.63 [0.26, 1.56] | 1 study · 135 participants | Very low |
Single‐dose vs short‐course (3‐7 days) antibiotics Recurrence · children with lower urinary tract infection Antibiotics for treating lower urinary tract infection in children (2012) · Cochrane | RR 1.5 [0.43, 5.26] | 2 studies · 145 participants | Very low |
Single‐dose vs short‐course (3‐7 days) antibiotics Re‐infection · children with lower urinary tract infection Antibiotics for treating lower urinary tract infection in children (2012) · Cochrane | RR 0.16 [0.02, 1.26] | 1 study · 45 participants | Very low |
Single‐dose vs conventional 10‐day antibiotic treatment Persistent bacteriuria · children with lower urinary tract infection Antibiotics for treating lower urinary tract infection in children (2012) · Cochrane | RR 2.01 [1.06, 3.8] | 6 studies · 228 participants | Very low |
Single‐dose vs conventional 10‐day antibiotic treatment Persistent symptoms · children with lower urinary tract infection Antibiotics for treating lower urinary tract infection in children (2012) · Cochrane | RR 0.29 [0.03, 2.5] | 1 study · 30 participants | Very low |
Single‐dose vs conventional 10‐day antibiotic treatment Persistent bacteriuria and symptoms · children with lower urinary tract infection Antibiotics for treating lower urinary tract infection in children (2012) · Cochrane | RR 1.83 [0.18, 18.84] | 1 study · 46 participants | Very low |
Single‐dose vs conventional 10‐day antibiotic treatment Recurrence · children with lower urinary tract infection Antibiotics for treating lower urinary tract infection in children (2012) · Cochrane | RR 1.38 [0.55, 3.5] | 2 studies · 79 participants | Very low |
Intervention NR Persistent bacteriuria · children with lower urinary tract infection Antibiotics for treating lower urinary tract infection in children (2012) · Cochrane | RR 1.1 [0.68, 1.77] | 3 studies · 265 participants | Very low |
Intervention NR Recurrence · children with lower urinary tract infection Antibiotics for treating lower urinary tract infection in children (2012) · Cochrane | RR 1.14 [0.7, 1.86] | 4 studies · 363 participants | Very low |
Intervention NR SAEs ‐ formoterol versus placebo ( · patients with chronic asthma Regular treatment with formoterol for chronic asthma: serious adverse events (2012) · Cochrane | OR 1.57 [1.05, 2.37] | 19 studies · 6646 participants | High |
Intervention NR SAEs ‐ formoterol versus salbutamol ( · patients with chronic asthma Regular treatment with formoterol for chronic asthma: serious adverse events (2012) · Cochrane | OR 0.72 [0.37, 1.43] | 9 studies · 2119 participants | Moderate |
Intervention NR Mortality (all‐cause) ‐ formoterol versus placebo ( · patients with chronic asthma Regular treatment with formoterol for chronic asthma: serious adverse events (2012) · Cochrane | OR 1.52 [0.24, 9.71] | 14 studies · 5463 participants | Moderate |
Intervention NR Mortality (all‐cause) ‐ formoterol versus salbutamol ( · patients with chronic asthma Regular treatment with formoterol for chronic asthma: serious adverse events (2012) · Cochrane | OR 0.5 [0.03, 8.05] | 6 studies · 1418 participants | Moderate |
Intervention NR SAEs ‐ formoterol versus placebo ( · patients with chronic asthma (children) Regular treatment with formoterol for chronic asthma: serious adverse events (2012) · Cochrane | OR 2.82 [1.16, 6.83] | 5 studies · 1335 participants | High |
Intervention NR SAEs ‐ formoterol versus salbutamol · patients with chronic asthma (children) Regular treatment with formoterol for chronic asthma: serious adverse events (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Persistent bacteriuria at 6 months · Patients with covert bacteriuria in children Interventions for covert bacteriuria in children (2012) · Cochrane | RR 0.35 [0.18, 0.7] | 1 study · 42 participants | Low |
Intervention NR Persistent bacteriuria at 2 years · Patients with covert bacteriuria in children Interventions for covert bacteriuria in children (2012) · Cochrane | RR 0.33 [0.02, 5.34] | 2 studies · 241 participants | Very low |
Intervention NR Persistent bacteriuria at 4 to 5 years · Patients with covert bacteriuria in children Interventions for covert bacteriuria in children (2012) · Cochrane | OR 0.39 [0.26, 0.57] | 3 studies · 444 participants | Very low |
Intervention NR Covert bacteriuria · Patients with covert bacteriuria in children Interventions for covert bacteriuria in children (2012) · Cochrane | RR 0.71 [0.48, 1.03] | 1 study · 61 participants | Low |
Intervention NR Cystitis (lower UTI) · Patients with covert bacteriuria in children Interventions for covert bacteriuria in children (2012) · Cochrane | RR 2.01 [0.78, 5.19] | 2 studies · 266 participants | Very low |
Intervention NR Pyelonephritis · Patients with covert bacteriuria in children Interventions for covert bacteriuria in children (2012) · Cochrane | RR 0.72 [0.23, 2.23] | 2 studies · 247 participants | Very low |
Intervention NR Renal growth · Patients with covert bacteriuria in children Interventions for covert bacteriuria in children (2012) · Cochrane | no estimate extracted | 2 studies · 355 participants | Very low |
Medial epicondylectomy plus oral steroids vs oral steroids alone Change in sensory score after one year · patients with nerve damage in leprosy Decompressive surgery for treating nerve damage in leprosy (2012) · Cochrane | no estimate extracted | 1 study · 57 participants | Very low |
Medial epicondylectomy plus oral steroids vs oral steroids alone Proportion of ulnar nerves with sensory improvement after one year · patients with nerve damage in leprosy Decompressive surgery for treating nerve damage in leprosy (2012) · Cochrane | RR 1.12 [0.71, 1.77] | 1 study · 62 participants | Very low |
Medial epicondylectomy plus oral steroids vs oral steroids alone Change in motor score after one year · patients with nerve damage in leprosy Decompressive surgery for treating nerve damage in leprosy (2012) · Cochrane | no estimate extracted | 1 study · 57 participants | Very low |
Medial epicondylectomy plus oral steroids vs oral steroids alone Proportion of ulnar nerves with motor improvement after one year · patients with nerve damage in leprosy Decompressive surgery for treating nerve damage in leprosy (2012) · Cochrane | RR 0.91 [0.64, 1.28] | 1 study · 62 participants | Very low |
Medial epicondylectomy plus oral steroids vs oral steroids alone Change in sensory score after two years · patients with nerve damage in leprosy Decompressive surgery for treating nerve damage in leprosy (2012) · Cochrane | no estimate extracted | 1 study · 57 participants | Very low |
Medial epicondylectomy plus oral steroids vs oral steroids alone Change in motor score after two years · patients with nerve damage in leprosy Decompressive surgery for treating nerve damage in leprosy (2012) · Cochrane | no estimate extracted | 1 study · 57 participants | Very low |
Urokinase (any strength) vs placebo Restored patency · patients with occluded central venous catheter Interventions for restoring patency of occluded central venous catheter lumens (2012) · Cochrane | RR 2.09 [1.47, 2.95] | 2 studies · 287 participants | Low |
Urokinase (any strength) vs placebo Adverse effects · patients with occluded central venous catheter Interventions for restoring patency of occluded central venous catheter lumens (2012) · Cochrane | RR 2.88 [0.38, 21.93] | 1 study · 72 participants | Very low |